Aldeyra Therapeutics Inc ALDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALDX is a good fit for your portfolio.
News
-
Aldeyra, Eagle Pharmaceuticals, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
-
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
-
Investigation Alert: Aldeyra, Eagle Pharmaceuticals, and Blue Ridge Bankshares: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
-
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
-
Aldeyra Therapeutics to Host Investor Roundtable Q&A
-
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
-
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
-
Aldeyra Therapeutics Says Additional Trial Needed For FDA Approval of Dry-Eye Disease Treatment
Trading Information
- Previous Close Price
- $4.09
- Day Range
- $4.08–4.21
- 52-Week Range
- $1.42–8.38
- Bid/Ask
- $3.91 / $4.30
- Market Cap
- $246.57 Mil
- Volume/Avg
- 200,009 / 328,602
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.aldeyra.com
Comparables
Valuation
|
Metric
|
ALDX
|
MORF
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.17 | 4.58 | 1.84 |
Price/Sales | — | — | 3,220.91 |
Price/Cash Flow | — | — | — |
Price/Earnings
ALDX
MORF
PLRX
Financial Strength
|
Metric
|
ALDX
|
MORF
|
PLRX
|
|---|---|---|---|
Quick Ratio | 6.14 | 23.71 | 15.95 |
Current Ratio | 6.50 | 24.13 | 16.12 |
Interest Coverage | −17.02 | — | −138.69 |
Quick Ratio
ALDX
MORF
PLRX
Profitability
|
Metric
|
ALDX
|
MORF
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −17.68% | −20.07% | −23.39% |
Return on Equity (Normalized) | −21.58% | −20.72% | −25.61% |
Return on Invested Capital (Normalized) | −22.95% | −24.50% | −29.08% |
Return on Assets
ALDX
MORF
PLRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Ygslhntsq | Wck | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Qhwcjxtb | Zjsztz | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Trsgsxnq | Gysjhz | $118.7 Bil | |||
| Moderna Inc
MRNA
| Jqsrlpgc | Zbnq | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rvqwkfzd | Jmnfknz | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Lyyddncn | Gyvk | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Gtfmhnqk | Bbgcs | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pyldyqpz | Scrdc | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Pgqjrqfhw | Mgm | $15.0 Bil | |||
| Incyte Corp
INCY
| Dfbqxkbs | Ggvscn | $13.5 Bil |